Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 284 results
Press release cover image

Aug 19, 2026

SandboxAQ Launches AQPotency, Bringing Ultrafast Virtual Screening to Drug Discovery Without a Solved Protein Structure

PALO ALTO, Calif., Aug. 19, 2026 /PRNewswire/ -- SandboxAQ today announced the general availability of AQPotency, its Large Quantitative Model (LQM) for predicting how well a potential drug will work, now available on Claude via Model Context Protocol (MCP). For any disease target, AQPotency scores how strongly candidate molecules are likely to act on it, and it does this without the expensive, time-consuming lab work that older methods depend on. Drug discovery teams can now rank enormous libra
Press release cover image

Aug 18, 2026

Asimov Announces Cell Line Development Partnership with Kaigene to Advance Multispecific Antibody for Autoimmune Disease

BOSTON, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a cell line development partnership with Kaigene, a biotechnology company pioneering next-generation antibody therapeutics for pathogenic antibody-mediated autoimmune diseases. The partnership covers a full cell line development campaign, from vector design and synthesis through the production and shipment of a high-titer research ce
A minimalist representation of a molecule and a test tube in a dark color scheme.

Aug 17, 2026

Pharma Races to Scale AI as Billions Flow into Drug Discovery

The landscape of AI-driven drug discovery is rapidly evolving, fueled by substantial investments that prioritize comprehensive platforms over individual drug assets. This shift is characterized by advanced AI reasoning workflows that enhance biomedical research across diverse datasets, including genomics and proteomics, enabling the development of more sophisticated models of biological complexity.Key players like Isomorphic Labs are leading this charge, with a focus on creating a versatile desi
A minimalist representation of a pill and a molecule in flat design.

Aug 15, 2026

Lantern Pharma Says AI Cuts First-In-Human Drug Development Cost To $2 Million-$3 Million

Lantern Pharma has reported a significant reduction in the costs associated with advancing oncology programs to first-in-human clinical trials, utilizing its AI-driven drug development model. The company claims that this approach allows for development costs to be as low as $2 million to $3 million per program, a stark contrast to the industry standard of $25 million to $100 million.The company's RADR platform leverages artificial intelligence and machine learning to expedite the drug developmen
Press release cover image

Aug 15, 2026

Aizen Enters into Collaboration with San Diego Biopharma to Advance Oral Biologics

Multi-program deal with revenue potential of $100 million per targetSAN DIEGO, Aug. 15, 2026 /PRNewswire/ -- Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San Diego-based, public biotech to design oral peptide therapeutics using its DaX™ foundation model. The agreement provides Aizen with several million dollars in initial revenue and up to $100 million in milestones for each nominated target."Oral
Flat illustration of a tissue sample and biological chip in a lab setting

Aug 12, 2026

Human Biological Datacenter to Launch to Train World Model of Human Biology

Vivodyne has unveiled an expansive human biological datacenter that aims to revolutionize drug discovery by enabling unprecedented large-scale testing of human tissues.The newly launched facility features 12 robotic HIVE laboratories capable of conducting controlled trials on an estimated 3.1 million large human tissues annually, a capacity that significantly exceeds the total of all U.S. clinical trials combined. Central to this innovation is the Series 2 TissueDisk, a biological chip that can
A glass vial with a drug compound on a lab bench

Aug 12, 2026

Ohio State launches AI-enabled biotech initiative to speed drug discovery

The Ohio State University has unveiled Buckeye BioLaunch, an innovative initiative aimed at accelerating drug discovery through AI technology.This program integrates clinical and genomic data with academic research, leveraging resources from the Ohio State Wexner Medical Center and its Comprehensive Cancer Center, as well as the Colleges of Medicine and Pharmacy. The overarching goal is to establish a robust pipeline for therapeutic development, fostering economic growth and job creation in Cent
Press release cover image

Aug 11, 2026

Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence

Once-weekly intravenous treatment was associated with reported improvements in finger function and walking ability, with no adverse events reported during treatment BOSTON, MA, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering galectin-targeting carbohydrate therapeutics, today announced positive clinical results from the first patient treated with PLICID, an investigational galectin antagonist for Chronic Inflammatory Demyelinat
Press release cover image

Aug 10, 2026

Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI

New AI co-innovation hub in London brings together AWS engineers, AI specialists, and applied scientists alongside Novo Nordisk research and development teams to increase productivity and help reduce the time to market for future medicines.Agreement establishes AWS as Novo Nordisk's preferred cloud provider and strategic AI partner to accelerate drug discovery and modernise its technology infrastructure, preparing for the next generation of medicines. Bagsværd, Denmark, 10 August, 2026 - Novo No
Press release cover image

Aug 10, 2026

Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology

The collaboration will leverage CrystalO's ion channel small-molecule drug discovery platform and Almirall’s expertise in skin science to jointly advance an innovative small-molecule program in medical dermatology.CrystalO will conduct candidate discovery, optimization, IND-enabling studies and early clinical development to deliver clinical proof of concept (POC), while Almirall will lead subsequent global development, manufacturing and commercialization holding exclusive rights outside mainland
A test tube with green solution in a lab setting

Aug 8, 2026

Build AI Agents for Life Sciences with NVIDIA BioNeMo and Nebius in partnership with J.P.Morgan

NVIDIA, in collaboration with J.P. Morgan and Nebius, is spearheading a workshop aimed at empowering life sciences professionals to harness AI agents for research and drug development.AI agents are revolutionizing the life sciences landscape by enhancing processes such as literature analysis and drug discovery. The upcoming workshop will focus on the BioNeMo Agent Toolkit, which provides developers and life sciences teams with the tools necessary to create AI-driven workflows across various doma
A nanobody protein sample on a lab bench with a research notebook in the background.

Aug 7, 2026

Stanford's AI agents designed a drug Merck later built, too

Stanford University's recent advancements in AI-driven drug development signal a shift from traditional single-agent models to a collaborative network of specialized agents.At the VB Transform 2026 conference, James Zou, a biomedical data science associate professor at Stanford, presented a transformative approach to AI in drug discovery. His team developed a "Virtual Lab" that mimics a physical research environment, utilizing multiple AI agents that specialize in various domains. This innovativ